Cerecor Inc. (CERC)
(Delayed Data from NSDQ)
$5.57 USD
+0.13 (2.39%)
Updated May 3, 2019 04:00 PM ET
After-Market: $5.56 (%) 5:22 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
0 items in cart
Avalo Therapeutics, Inc. [CERC]
Reports for Purchase
Showing records 1 - 20 ( 55 total )
Company: Avalo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 10.00
Company: Avalo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Price: 24.95
Company: Avalo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Price: 24.95
Company: Avalo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Price: 24.95
Company: Avalo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pediatric Portfolio Sale Removes Debt Overhang; Raising Target to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Avalo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CERC-802 Receives Fast Track Designation From FDA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Avalo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Financial Results Reported; Slight Revenue Miss, But Guidance Maintained; Bottom-Line Beat; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Avalo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CERC-802 Investigational New Drug Application Accepted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Avalo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Price: 24.95
Company: Avalo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Key Natural History Study in Ultra-Rare Congenital Disorders of Glycosylation Starts Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Avalo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Surveying the Parkinson''s Disease Treatment Continuum: KOL Conference Call Recap
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 25.00
Company: Avalo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CERC-301 Final Phase 1 Results Underscore Promise; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Avalo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q19 Financial Results Reported; Sales Exceed Expectations; Multiple Catalysts Ahead; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Avalo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Avalo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CERC-801 Phase 1 Dosing Completion; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Avalo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Interim CERC-301 Phase 1 Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Avalo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Avalo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Leadership Transition Unlikely to Affect Trajectory; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Avalo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Melding a Commercial Platform With Ultra-Rare Drug Development; Initiating at Buy and $11 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 100.00